Concentrates of coagulation factors VIII and IX have good haemostatic effects on acute bleeding and during surgical intervention in patients with hemophilia A and B. However, the current agents used in this setting are mostly short-acting, making therapy troublesome for patients. Currently, new clotting factor concentrates are becoming available, or are in advanced clinical studies which will significantly improve the treatment for patients with hemophilia A and B. Various bioengineering concepts have been applied to modified recombinant FVIII, FIX and FVII proteins.1 These different technologies were summarised in an educational presentation during the 2015 annual EHA meeting by Dr. Johannes Oldenburg (University Clinic Bonn, Germany).

(BELG J HEMATOL 2015;6(3):130–1)